Research programme: RNAi therapeutics - SomaGenics

Drug Profile

Research programme: RNAi therapeutics - SomaGenics

Alternative Names: Short hairpin RNAs - SomaGenics; shRNAs - SomaGenics; sshRNA™

Latest Information Update: 01 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SomaGenics
  • Developer Arbutus Biopharma; Roche; SomaGenics
  • Class Small interfering RNA
  • Mechanism of Action RNA interference; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hepatitis C; Hepatitis D
  • Research Diabetic foot ulcer

Most Recent Events

  • 01 Dec 2016 Preclinical development in Hepatitis-C in still underway USA (Parenteral) (SomaGenics pipeline, November 2016)
  • 01 Dec 2016 Preclinical trials in Hepatitis D in USA (Parenteral) before December 2016 (SomaGenics website, November 2016)
  • 29 Nov 2016 Research programme: RNAi therapeutics - SomaGenics is available for licensing as of 29 Nov 2016. http://www.somagenics.com/therapeutic-sshrnas
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top